Related Experiment Video
Updated: May 2, 2026
10:27
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
23.9K
Interstitial granulomatous dermatitis successfully treated with etanercept
Zavier Shawkat Ahmed1, Sabaa Joad1, Manpreet Singh1
1Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Jamaica, NY, U.S.A.
The American Journal of Case Reports
|March 14, 2014
Summary
Interstitial Granulomatous Dermatitis (IGD) is a rare skin condition. This case study shows successful treatment of IGD associated with rheumatoid arthritis using etanercept, an anti-TNF antibody.
Area of Science:
- Dermatology
- Rheumatology
- Immunology
Background:
- Interstitial Granulomatous Dermatitis (IGD) is a rare skin condition characterized by erythematous and violaceous plaques, often accompanied by pruritus and pain.
- The etiology of IGD is unknown but frequently linked to autoimmune diseases and adverse drug reactions.
- Diagnosis is confirmed via biopsy, and effective treatment strategies remain under investigation.
Purpose of the Study:
- To report a successful treatment outcome for a patient diagnosed with Interstitial Granulomatous Dermatitis.
- To investigate the efficacy of etanercept in managing IGD associated with rheumatoid arthritis.
Main Methods:
- A case report detailing a 51-year-old female patient with biopsy-proven Interstitial Granulomatous Dermatitis.
- The patient had co-existing rheumatoid arthritis.
- Treatment involved the administration of etanercept, a biologic therapy targeting TNF-alpha.
Main Results:
- Successful treatment of Interstitial Granulomatous Dermatitis was achieved with etanercept therapy.
- The patient experienced resolution of symptoms associated with IGD.
Conclusions:
- Anti-TNF antibodies, such as etanercept, demonstrate potential clinical efficacy in the treatment of Interstitial Granulomatous Dermatitis.
- This finding suggests a promising therapeutic avenue for this rare dermatological condition.
